Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
7.38
+0.22 (3.07%)
At close: Jun 26, 2025, 4:00 PM
7.59
+0.21 (2.85%)
After-hours: Jun 26, 2025, 7:05 PM EDT
Fulcrum Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover Fulcrum Therapeutics stock have a consensus rating of "Hold" and an average price target of $6.29, which forecasts a -14.77% decrease in the stock price over the next year. The lowest target is $2 and the highest is $12.
Price Target: $6.29 (-14.77%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Fulcrum Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 0 | 0 |
Buy | 2 | 2 | 2 | 2 | 3 | 3 |
Hold | 6 | 5 | 5 | 5 | 3 | 3 |
Sell | 1 | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 10 | 9 | 9 | 9 | 7 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Piper Sandler | Piper Sandler | Buy Maintains $6 → $9 | Buy | Maintains | $6 → $9 | +21.95% | May 29, 2025 |
Leerink Partners | Leerink Partners | Hold → Buy Upgrades $4 → $12 | Hold → Buy | Upgrades | $4 → $12 | +62.60% | May 23, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Hold → Buy Upgrades $10 | Hold → Buy | Upgrades | $10 | +35.50% | May 15, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $4 | Hold | Reiterates | $4 | -45.80% | Feb 26, 2025 |
RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | -45.80% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
n/a
from 80.00M
Revenue Next Year
318.24K
EPS This Year
-1.18
from -0.16
EPS Next Year
-1.23
from -1.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | 1.6M | n/a | ||
Avg | n/a | 318,240 | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.14 | -1.16 | -1.05 | ||
Avg | -1.18 | -1.23 | -1.17 | ||
Low | -1.20 | -1.28 | -1.26 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.